Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03305293 and Topotecan in Relapsed Ovarian Cancer
NCT06930755Phase 1Recruiting
- Sponsor
- Nerviano Medical Sciences
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itareparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Nerviano Medical Sciences. Primary endpoint: Number of Participants with Adverse Events at 6 months. Started May 2026; status: recruiting.
02
Drugs
itareparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06930755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930755.